Want to see AU:NTI full AI Analyst Report?

Neurotech International (NTI) Price & Analysis

11 Followers

NTI Stock Chart & Stats

AU$0.02

AU$0.00(0.00%)

At close: Jan 09 4:00 PM EST

AU$0.02

AU$0.00(0.00%)

Day’s Range― - ―

52-Week RangeAU$0.01 - AU$0.03

Previous CloseN/A

Volume11.09K

Average Volume (3M)768.84K

Market Cap

AU$17.13M

Enterprise ValueAU$9.84M

Total Cash (Recent Filing)AU$6.34M

Total Debt (Recent Filing)AU$0.00

Price to Earnings (P/E)―

Beta1.25

Next Earnings

Sep 02, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)>-0.01

Shares Outstanding1,317,741,700

10 Day Avg. Volume770,041

30 Day Avg. Volume768,844

Financial Highlights & Ratios

PEG Ratio-0.02

Price to Book (P/B)5.26

Price to Sales (P/S)6.36

P/FCF Ratio-1.72

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Zero Financial Leverage (no Debt)A zero-debt balance sheet materially reduces solvency and interest-rate risk, giving the company flexibility while it invests in R&D. This durable strength improves access to financing on better terms, and preserves cash flow priority for clinical programs during multi-quarter funding cycles.

Focused Cannabinoid R&D SpecializationA concentrated, science-driven focus on cannabinoid therapies creates domain expertise and potential proprietary assets. This strategic clarity supports durable competitive advantages in niche regulatory, clinical and partnership pathways, enhancing long-term value if clinical milestones are met and IP is protected.

Revenue Rebound With Very High Gross MarginA marked revenue recovery from near-zero and exceptionally high reported gross margin indicate initial commercial traction and favorable product economics. If sustained and scaled, such margins can translate into operating leverage that narrows losses and supports self-funding of development over multiple quarters.

Bears Say

Accelerating Negative Free Cash FlowWorsening free cash flow reflects growing cash burn as activities ramp, creating a durable financing requirement. Persistent FCF deficits increase dilution risk, elevate dependency on external capital and constrain the firm's ability to self-fund trials or expand operations over a multi-quarter horizon.

Large Operating And Net Losses Relative To RevenueOperating costs massively exceed current revenue, implying the business is far from break-even. Structural loss-making at this scale threatens runway and requires sustained revenue growth or cost reduction to achieve durable profitability; otherwise losses will keep pressuring equity and financing options.

Material Decline In Equity And Capital BufferA markedly reduced equity base weakens the company's capitalization and absorption capacity for losses, increasing the likelihood of future equity raises. This erosion is a lasting constraint on financial flexibility and can dilute existing shareholders while funding prolonged R&D programs.

Neurotech International News

Neurotech International Options Lapse, Reducing Potential Share Dilution

Neurotech International ( ($AU:NTI) ) has issued an update. Neurotech International has confirmed the expiry and cessation of...

4h ago

NTI

Neurotech Director Options Expire Without Exercise

The latest update is out from Neurotech International ( ($AU:NTI) ). Neurotech International has reported a change in...

2M ago

NTI

Neurotech Options Lapse, Trimming Potential Future Dilution

An update from Neurotech International ( ($AU:NTI) ) is now available. Neurotech International has notified the market that...

2M ago

NTI

Maybank Securities Exits Substantial Holder Position in Neurotech International

An announcement from Neurotech International ( ($AU:NTI) ) is now available. Neurotech International has disclosed that Maybank Securities...

2M ago

NTI

Neurotech Showcases Paediatric Neurology Drug NTI164 at Hong Kong Investment Summit

The latest update is out from Neurotech International ( ($AU:NTI) ). Neurotech International will present its lead cannabinoid-based...

3M ago

NTI

Neurotech Director Mark Davies Increases Indirect Shareholding

Neurotech International ( ($AU:NTI) ) just unveiled an update. Neurotech International has disclosed a change in director Mark...

3M ago

NTI

Neurotech clears secondary trading for new share issue

The latest announcement is out from Neurotech International ( ($AU:NTI) ). Neurotech International has issued new fully paid...

3M ago

NTI

Neurotech International Seeks ASX Quotation for 21.4 Million New Shares

Neurotech International ( ($AU:NTI) ) just unveiled an announcement. Neurotech International Limited has applied for quotation on the...

3M ago

NTI

Neurotech to Highlight Paediatric Neurology Pipeline at NWR Virtual Healthcare Conference

Neurotech International ( ($AU:NTI) ) just unveiled an update. Neurotech International, a clinical-stage biopharmaceutical company specialising in paediatric...

3M ago

NTI

Neurotech Flags Risks and Uncertainties in Neurodevelopmental Drug Strategy

The latest announcement is out from Neurotech International ( ($AU:NTI) ). Neurotech International has outlined its current corporate...

3M ago

NTI

NTI FAQ

What was Neurotech International Ltd.’s price range in the past 12 months?

Neurotech International Ltd. lowest share price was AU$0.01 and its highest was AU$0.03 in the past 12 months.

What is Neurotech International Ltd.’s market cap?

Neurotech International Ltd.’s market cap is AU$17.13M.

When is Neurotech International Ltd.’s upcoming earnings report date?

Neurotech International Ltd.’s upcoming earnings report date is Sep 02, 2026 which is in 65 days.

How were Neurotech International Ltd.’s earnings last quarter?

Neurotech International Ltd. released its earnings results on Feb 26, 2026. The company reported -AU$0.07 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.07.

Is Neurotech International Ltd. overvalued?

According to Wall Street analysts Neurotech International Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Neurotech International Ltd. pay dividends?

Neurotech International Ltd. does not currently pay dividends.

What is Neurotech International Ltd.’s EPS estimate?

Neurotech International Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Neurotech International Ltd. have?

Neurotech International Ltd. has 1,317,741,700 shares outstanding.

What happened to Neurotech International Ltd.’s price movement after its last earnings report?

Neurotech International Ltd. reported an EPS of -AU$0.07 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 7.692%.

Which hedge fund is a major shareholder of Neurotech International Ltd.?

Currently, no hedge funds are holding shares in AU:NTI

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Neurotech International Stock Smart Score

Neutral

Fundamentals

Return on Equity

-87.19%

Trailing 12-Months

Asset Growth

5.87%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Neurotech International Ltd.

Neurotech International Limited (NTI.AX), along with its subsidiaries, is an Australian firm dedicated to the research, development, and manufacture of innovative medical devices and solutions. The company's primary focus lies in advancing and commercializing its Mente platform, a technological system designed to monitor and facilitate home-based therapies. This includes its Mente Autism product, specifically aimed at the diagnosis and treatment of autism spectrum disorder. Additionally, Neurotech actively undertakes various medical research projects and engineers new technological instruments. The company was established in 2016 and maintains its headquarters in Nedlands, Australia.